drugset / Trial / NCT07054190
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
Timeline
- Start
- 2025-09-09
- Primary completion
- 2027-07-31
- Completion
- 2027-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Giredestrant | Small molecule | — | Oral |
| Subject | Inavolisib | Small molecule | — | Oral |
| Subject | Letrozole | Other / unclassified | — | Oral |
| Subject | Ribociclib | Small molecule | — | Oral |